Discovery/R&D

1. RNA-Engineered Cell Therapy With Cartesian's Dr. Murat Kalayoglu 6/10/2021

   Cartesian President & CEO Murat Kalayoglu, M.D., Ph.D. has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year. With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech.

2. Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D. 4/10/2024

   Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.

3. COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD 7/12/2023

   Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next.

   Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

4. Inhalable mAbs & Vaccines With TFF's Glenn Mattes 12/6/2021

   Glenn Mattes' TFF Pharmaceuticals is looking to break the parenteral barrier by manufacturing biologics — mAbs and vaccines, more specifically — that can be inhaled, rather than injected. It's a timely endeavor, and TFF's business model is a collaborative one that seeks to explore dry powder biologic options through partnership, in addition to its own pipeline. On this episode of the Business of Biotech, the veteran biopharma CEO shares the company's vision and the technology that's bringing it into focus.

5. Running Interference: RNAi With Silence Therapeutics' Craig Tooman 5/18/2022

   Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of RNAi gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases.

6. The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson 6/4/2025

   On this week's Business of Biotech, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere.

7. RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D. 1/12/2025

   In close partnership with Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA's Anna Rose Welch to learn about the venture, dubbed the Johns Hopkins University RNA Innovation Center.

8. RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D. 11/8/2023

   Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken – and others – before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that.

9. High-Throughput Discovery With BIOPTIC's Andrey Dobry 1/19/2025

   Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and advanced screening are reshaping drug discovery. Learn more about BIOPTIC’s bold vision, the challenges of data access, and overcoming skepticism in the biotech industry.

10. Pyxis Oncology's Lara Sullivan, M.D. On Site-Specific ADCs And Change Management 6/20/2022

    To fully appreciate the work Pyxis Oncology is doing in its development of site-specific ADCs for a number of oncological indications under the leadership of Lara Sullivan, M.D., you need to understand the work that shaped her leadership style. On this episode of the Business of Biotech, Dr. Sullivan shares the science and technology driving progress at Pyxis, but she also serves up a master class on change management, honed during her tenure managing high-stakes product portfolios at Pfizer. If you want to be a better leader, don't miss this one.